-
Guangzhou Base
- 5200 m² GMP and Application Center
-
Complete, Efficient and Stable Manufacturing Capacity and Quality Control
- An enlarged and stable manufacturing process in order to keep important parameters stable in the whole process
- The gene editing efficiency with guaranteed efficacy and safety
-
Poster Presentation at the 61st ASH Annual Meeting
In December 2019, at the 61st ASH Annual Meeting, presented preclinical data on ET-01, its leading therapeutic program for patients with β-Thalassemia Major, during the 61st American Society of Hematology (ASH) Annual Meeting.
The presentation highlighted selected data from scaled-up manufacturing campaigns at clinical scale and IND-enabling preclinical studies of ET-01.
